National Institute on Drug Abuse (NIDA)
6001 Executive Boulevard
56 articles with National Institute on Drug Abuse (NIDA)
BreviTest Awarded SBIR Phase II Grant from National Institute on Drug Abuse to Commercialize Device for Rapid Opioid Testing
Houston, TX - BreviTest Technologies has been awarded a $1,500,000 grant from the National Institute on Drug Abuse of the National Institutes of Health to further the commercialization of its point-of-care analyzer for rapid opioid urine testing.
Advanced Brain Monitoring, Inc. announced $1.5 million awarded by the National Institute on Drug Abuse to develop and validate the Cannabis Impairment Detection Application, a fieldable, easily-applied system to generate a cannabis-related impairment index using wireless EEG/ECG with tablet-based neuropsychological tests.
Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal
Kinoxis Therapeutics Pty Ltd has been awarded a major grant from the US National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA).
Ensysce Biosciences Receives Multi-Year NIH HEAL Grant to Develop a Novel Opioid-Use-Disorder (OUD) Medication
Company proprietary TAPP and MPAR overdose technology to aid a most vulnerable patient population.
NYU Langone Health Launches New Center to Study the Drivers and Consequences of the National Opioid Epidemic
Watch a video of Dr. Magdalena Cerdá outline the mission and goals of the Center for Opioid Epidemiology and Policy
Montefiore and Einstein Aim to Reduce Opioid Overdose Deaths by 40 Percent
Covanta partners with law enforcement to help protect the public and the environment
National Health Observance Week Helps SHATTER THE MYTHS® about Drug and Alcohol Misuse
MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate
Preclinical studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids
Phoenix PharmaLabs Awarded NIH/NIDA Grant to Study Non-Addictive Opioid PPL-103 for Potential use as Cocaine Addiction Therapy Drug
This research is supported under award number R41DA044894.
Request comes after NIDA and the FDA remove information related to the safety of kratom from NIDA's official website.
Ruling highlights FDA's responsibility to seize illegal, counterfeit, and contaminated forms of popular dietary supplement
Alkermes' VIVITROL and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse
This is the second study published in the past month comparing these two medications and it provides additional evidence supporting the use of VIVITROL as an effective treatment option for patients.
Addex Therapeutics Initiates New Study In Collaboration With U.S. National Institute on Drug Abuse (NIDA) With ADX88178 In Non-Human Primate Model Of Cocaine Addiction
Embera NeuroTherapeutics, Inc. Receives $11M Grant From National Institute on Drug Abuse (NIDA) For The Clinical Development Of EMB-001 For The Treatment Of Cocaine Addiction
Cerecor Inc. Announces $1.0 Million Research & Development Grant From The National Institute on Drug Abuse (NIDA) At The NIH
Eagle Pharma And NIH (NIH/National Institute on Drug Abuse (NIDA)) Enter Into Agreement To Explore Use Of Ryanodex In MDMA (Ecstasy) And Methamphetamine Intoxication
Sosei Group Corporation Subsidiary Heptares Awarded $5.5 Million Research & Development Grant From National Institute on Drug Abuse (NIDA)
Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding By The National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) Under The Small Business Innovation Research Funding Award Program
Technical Resources International, Inc. And Nuventra Pharma Sciences To Provide Pharmacokinetic And Pharmacodynamic Services To The National Institute on Drug Abuse (NIDA)